Document is current
Any future updates will be listed below
-
Authors
Nicholls, Stephen J.
Ditmarsch, Marc
Kastelein, John J. https://orcid.org/0000-0003-2018-4532
Rigby, Scott P.
Kling, Douglas
Curcio, Danielle L.
Alp, Nicholas John
Davidson, Michael H.
- License Information
-
More Information
Article History
Received: 19 December 2021
Accepted: 6 July 2022
First Online: 11 August 2022
Competing interests
: S.J.N. has received research support from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, IntraReDx, Roche, Sanofi-Regeneron and LipoScience and is a consultant for AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion and Boehringer Ingelheim. M.D. is Vice President of Research & Development for New Amsterdam Pharma. J.J.K. is employed part-time as Chief Scientific Officer by New Amsterdam Pharma and is an Emeritus Professor of Medicine at the University of Amsterdam, The Netherlands. S.P.R. is employed by MedPace, Inc. D.K. is employed as Chief Operating Officer by New Amsterdam Pharma. D.L.C. is employed as Senior Director of Clinical Operations by New Amsterdam Pharma. N.J.A. is employed by MedPace, Inc. M.H.D. is employed as Chief Executive Officer by New Amsterdam Pharma.
